Pierre Fabre Medicament, based in France, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
They are recognized for The 2nd largest dermo-cosmetics laboratory in the world and the 2nd largest private French pharmaceutical group.
One of their notable products is MILNACIPRAN HYDROCHLORIDE (PROCESS I), with a corresponding US DMF Number 11501.
Remarkably, this DMF maintains an Active status since its submission on May 11, 1995, highlighting commitment to regulatory compliance.